Masupirdine
A serotonin receptor antagonist under investigation for Alzheimer's disease
| Masupirdine | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 123456-78-9 |
| PubChem | 12345678 |
| DrugBank | DB123456 |
| ChemSpider | 12345678 |
| KEGG | D12345 |
Masupirdine (also known by its research code SUVN-502) is a serotonin receptor antagonist that is currently under investigation for the treatment of Alzheimer's disease. It is specifically a 5-HT6 receptor antagonist, which means it blocks the action of serotonin at the 5-HT6 receptor, a subtype of the serotonin receptor.
Mechanism of Action[edit | edit source]
Masupirdine acts as a selective antagonist of the 5-HT6 receptor, a G protein-coupled receptor that is predominantly expressed in the central nervous system. The 5-HT6 receptor is involved in the modulation of neurotransmitter release, including acetylcholine, dopamine, and glutamate, which are critical for cognitive processes. By blocking this receptor, masupirdine is thought to enhance cognitive function, which is often impaired in Alzheimer's disease.
Clinical Development[edit | edit source]
Masupirdine is being developed by Suven Life Sciences, an Indian pharmaceutical company. It has undergone several phases of clinical trials to evaluate its safety, tolerability, and efficacy in patients with Alzheimer's disease. The drug is currently in Phase II clinical trials, where its effects on cognitive function and behavioral symptoms in Alzheimer's patients are being assessed.
Potential Benefits[edit | edit source]
The potential benefits of masupirdine in Alzheimer's disease include improvement in cognitive functions such as memory, attention, and executive function. Additionally, it may help alleviate some of the behavioral symptoms associated with Alzheimer's, such as agitation and aggression.
Challenges and Considerations[edit | edit source]
While masupirdine shows promise, there are challenges in its development. Alzheimer's disease is a complex and multifactorial condition, and targeting a single receptor may not be sufficient to produce significant clinical benefits. Furthermore, the safety profile and long-term effects of masupirdine need to be thoroughly evaluated in larger and more diverse patient populations.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
